康寧傑瑞製藥(09966.HK)將呈列兩種雙特異性抗體之研究結果
康寧傑瑞製藥-B(09966.HK)公布,將於2021年美國臨床腫瘤學會年會呈列KN046(一種重組人源化PD-L1/CTLA-4雙特異性抗體)及KN026(一種基於Fc的抗HER2雙特異性抗體)的研究結果,美國臨床腫瘤學會為醫生及腫瘤學專業人士關愛癌症患者的世界領先專業機構。
KN046的臨床前及臨床試驗結果展現出良好的有效性,並表明KN046有望降低脫靶毒性。KN046旨在被開發為突破性腫瘤免疫特效藥。KN026正在中國進行數項I/II期臨床試驗,並正在美國進行一項I期臨床試驗。KN026已在晚期HER2+乳腺癌及GC/GEJ 患者中表現出良好的初步療效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.